Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Aharona Glatman-Freedman; Yael Hershkovitz; Zalman Kaufman; Rita Dichtiar; Lital Keinan-Boker; Michal Bromberg

doi:10.3201/eid2711.211886

Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Aharona Glatman-Freedman, Yael Hershkovitz, Zalman Kaufman, Rita Dichtiar, Lital Keinan-Boker, Michal Bromberg

School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.

Original language	English
Pages (from-to)	2919-2922
Number of pages	4
Journal	Emerging Infectious Diseases
Volume	27
Issue number	11
DOIs	https://doi.org/10.3201/eid2711.211886
State	Published - Nov 2021

Bibliographical note

Publisher Copyright:
© 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.

ASJC Scopus subject areas

Epidemiology
Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3201/eid2711.211886

Cite this

@article{cd12392236b845bcaac599959ebd55be,

title = "Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021",

abstract = "In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.",

author = "Aharona Glatman-Freedman and Yael Hershkovitz and Zalman Kaufman and Rita Dichtiar and Lital Keinan-Boker and Michal Bromberg",

year = "2021",

month = nov,

doi = "10.3201/eid2711.211886",

language = "English",

volume = "27",

pages = "2919--2922",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "11",

}

TY - JOUR

T1 - Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

AU - Glatman-Freedman, Aharona

AU - Hershkovitz, Yael

AU - Kaufman, Zalman

AU - Dichtiar, Rita

AU - Keinan-Boker, Lital

AU - Bromberg, Michal

PY - 2021/11

Y1 - 2021/11

N2 - In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.

AB - In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.

UR - http://www.scopus.com/inward/record.url?scp=85117942942&partnerID=8YFLogxK

U2 - 10.3201/eid2711.211886

DO - 10.3201/eid2711.211886

M3 - Article

C2 - 34570694

AN - SCOPUS:85117942942

SN - 1080-6040

VL - 27

SP - 2919

EP - 2922

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 11

ER -

Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this